Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maveropepimut-S (DPX-Survivac) with Cyclophosphamide and Epacadostat in Recurrent Ovarian Cancer
NCT02785250Phase 2Unknown
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Apr 2016
- Primary completion
- Oct 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of maveropepimut-S in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by ImmunoVaccine Technologies Inc. Primary endpoints: Safety as measured by adverse event reporting (CTCAE) up to 13 months and Objective Response Rate up to 13 months. Status: unknown.
02
Drugs
maveropepimut-S
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02785250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785250.